Related Experiment Video
Updated: Aug 12, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma
Daisuke Sano1, Hideki Matsuda, Yukari Ishiguro
1Department of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan. t046028d@yokohama-cu.ac.jp
Abstract:
Taxanes, a new class of antitumor drugs, are effective against a large number of human tumors, although there are problems with drug resistance. The novel taxane, IDN5109, is characterized by its high tolerability, antitumor efficacy, ability to overcome multidrug resistance, and oral bioavailabilty. We investigated the cellular response of IDN5109 to head and neck squamous cell carcinoma (HNSCC), and compared the antitumor activity of IDN5109 with that of paclitaxel. This is the first demonstration of antitumor effects of IDN5109 on HNSCC. In in vitro experiments, IDN5109 showed antiproliferative effects against HNSCC cell lines. After treatment with IDN5109, Bcl-2 and Bcl-XL were down-regulated, Bax was up-regulated, and caspase-3 was activated. After treatment with IDN5109, concentrations of both VEGF and IL-8 in the culture supernatant of HNSCC cells decreased. In in vivo experiments, the oral administration of IDN5109 showed antitumor effects against HNSCC tumor xenografts. Immunohistochemistry showed that IDN5109 inhibited tumor angiogenesis and induced apoptosis in HNSCC cells, producing a decreased blood vessel density and increased apoptosis index. On the basis of these results, IDN5109 is useful as a chemotherapeutic agent against HNSCC.
Insights
The novel taxane IDN5109 shows significant antitumor effects against head and neck squamous cell carcinoma (HNSCC). This drug overcomes resistance and demonstrates efficacy in both in vitro and in vivo models.
Area of Science:
- Oncology
- Pharmacology
Background:
- Taxanes are effective antitumor drugs but face challenges with drug resistance.
- IDN5109 is a novel taxane with high tolerability, antitumor efficacy, oral bioavailability, and the ability to overcome multidrug resistance.
Purpose of the Study:
- To investigate the cellular response of IDN5109 in head and neck squamous cell carcinoma (HNSCC).
- To compare the antitumor activity of IDN5109 with paclitaxel in HNSCC.
- To evaluate the potential of IDN5109 as a chemotherapeutic agent for HNSCC.
Main Methods:
- In vitro antiproliferative assays on HNSCC cell lines.
- Analysis of apoptosis-related proteins (Bcl-2, Bcl-XL, Bax, caspase-3) and signaling molecules (VEGF, IL-8) after IDN5109 treatment.
- In vivo studies using HNSCC tumor xenografts in mice with oral administration of IDN5109.
- Immunohistochemical analysis of tumor angiogenesis and apoptosis in xenografts.
Main Results:
- IDN5109 demonstrated antiproliferative effects on HNSCC cell lines.
- IDN5109 modulated apoptosis pathways by down-regulating Bcl-2/Bcl-XL, up-regulating Bax, and activating caspase-3.
- IDN5109 reduced VEGF and IL-8 concentrations in HNSCC supernatant.
- Oral IDN5109 inhibited HNSCC tumor xenograft growth, reduced tumor angiogenesis, and increased apoptosis in vivo.
Conclusions:
- IDN5109 exhibits significant antitumor activity against HNSCC.
- IDN5109 effectively inhibits tumor growth, angiogenesis, and induces apoptosis in HNSCC.
- IDN5109 shows promise as an orally bioavailable chemotherapeutic agent for HNSCC treatment.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy